Oral, inhaled, and intravenous antibiotic choice for treating pulmonary exacerbations in cystic fibrosis.

ABSTRACT:

Rationale

Patients with cystic fibrosis (CF) experience frequent pulmonary exacerbations (PExs). Clinicians manage these episodes of worsening signs and symptoms in a variety of ways.

Objectives

To characterize the antibiotic management and associated change in lung function following PExs.

Methods

We used 2003-2005 data from the Epidemiologic Study of Cystic Fibrosis to examine antibiotic treatment and the immediate and long-term lung function change associated with clinician reported PExs.

Results

A total of 45,374 PExs were reported in 13,194 unique patients. Most PExs (73%) were treated with oral antibiotics, while 39% were treated IV and 24% were treated with inhaled antibiotics. The likelihood of non-IV versus IV antibiotic treatment was associated with t

SUBMITTER: Wagener JS 

PROVIDER: S-EPMC4049300 | biostudies-literature | 2013 Jul

REPOSITORIES: biostudies-literature